NasdaqGM:HROWPharmaceuticals
How Investors May Respond To Harrow (HROW) Upsizing Its 2030 Unsecured Notes For Growth Flexibility
Harrow recently completed a private fixed‑income offering of US$50.0 million in 8.625% senior unsecured notes due September 15, 2030, issued at 100.25% of par and guaranteed by certain subsidiaries.
The new notes, fungible with Harrow’s existing US$250.0 million 2030 notes and sold to qualified institutional buyers under Rule 144A and Regulation S, further reshape the company’s capital structure to support general corporate and growth initiatives.
Now we’ll examine how this additional...